Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Offin

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
British Journal of Cancer|December 29, 2021
Immune biomarkers and response to checkpoint inhibition of BRAF<sup>V600</sup> and BRAF non-V600 altered lung cancersYonina R Murciano-Goroff, Terry Pak, Sebastian Mondaca, et al.
Cancer|August 31, 2019
Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancersMichael Offin, Daniel Feldman, Ai Ni, et al.
Cancer Research|November 24, 2021
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line ChemotherapyAlvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yuan Hao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2025
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief ReportGregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket TrialBob T Li, Ronglai Shen, Darren Buonocore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular SubtypesJason C Chang, Michael Offin, Christina Falcon, et al.
JCO Precision Oncology|September 4, 2024
Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung CancerYonina R Murciano-Goroff, Angela B-Y Hui, Jose A Araujo Filho, et al.
Journal of Hematology & Oncology|October 17, 2021
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiationAlvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yingqian A Zhan, et al.
Cancer Discovery|August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted CancerLars D Engstrom, Ruth Aranda, Laura Waters, et al.
Cancer Cell|October 15, 2021
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancerJoseph M Chan, Álvaro Quintanal-Villalonga, Vianne Ran Gao, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
British Journal of Cancer|December 29, 2021
Immune biomarkers and response to checkpoint inhibition of BRAF<sup>V600</sup> and BRAF non-V600 altered lung cancersYonina R Murciano-Goroff, Terry Pak, Sebastian Mondaca, et al.
Cancer|August 31, 2019
Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancersMichael Offin, Daniel Feldman, Ai Ni, et al.
Cancer Research|November 24, 2021
Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line ChemotherapyAlvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yuan Hao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2025
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief ReportGregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket TrialBob T Li, Ronglai Shen, Darren Buonocore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular SubtypesJason C Chang, Michael Offin, Christina Falcon, et al.
JCO Precision Oncology|September 4, 2024
Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung CancerYonina R Murciano-Goroff, Angela B-Y Hui, Jose A Araujo Filho, et al.
Journal of Hematology & Oncology|October 17, 2021
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiationAlvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yingqian A Zhan, et al.
Cancer Discovery|August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted CancerLars D Engstrom, Ruth Aranda, Laura Waters, et al.
Cancer Cell|October 15, 2021
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancerJoseph M Chan, Álvaro Quintanal-Villalonga, Vianne Ran Gao, et al.
Pageof 9